HUMACYTE INCHUMA
ASignal's systematic analysis rates HUMA as Bearish.
Reflects the latest available analysis · analyzed Oct 18, 2026
The case on HUMA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (34.9% YoY)
- High cash position ($79.9M) relative to market cap
- Current ratio of 6.21x indicates strong liquidity
- RSI near oversold territory (32.01), potential reversal signal
- Negative operating margin (-6649.26%) and net losses
- Negative free cash flow ($-58.39M)
- Negative EV/EBITDA and return on equity (-547.87%)
- High debt-to-equity ratio (2.14x)
- Overvalued metrics: PS ratio of 56.19x, EV/Revenue of 50.05x
- MACD below signal line with negative histogram
See the full verdict on HUMA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes HUMA
Most investors never get a second opinion, let alone several. ASignal runs HUMA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.